The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy

Description

Ketamine is a medication that came into clinical practice in the 1960's. Ketamine is used as an anesthetic and to provide pain relief. Recently, Ketamine was approved to treat drug resistant depression using subanesthetic doses. In the hospital setting, intravenous anesthetic dosages are used to treat unrelenting seizures known as status epilepticus in comatose patients. Ketamine in subanesthetic doses has not been tried as a treatment for medication resistant seizures in the outpatient setting. This study would like to examine the effectiveness of subanesthetic ketamine in outpatients who suffer from drug resistant epilepsy.

Conditions

Drug Resistant Epilepsy, Medically Refractory Epilepsy, Refractory Epilepsy

Talk to us

Study Overview

On this page

Study Details

Study overview

Ketamine is a medication that came into clinical practice in the 1960's. Ketamine is used as an anesthetic and to provide pain relief. Recently, Ketamine was approved to treat drug resistant depression using subanesthetic doses. In the hospital setting, intravenous anesthetic dosages are used to treat unrelenting seizures known as status epilepticus in comatose patients. Ketamine in subanesthetic doses has not been tried as a treatment for medication resistant seizures in the outpatient setting. This study would like to examine the effectiveness of subanesthetic ketamine in outpatients who suffer from drug resistant epilepsy.

A Pilot Study to Assess the Efficacy of Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy

The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy

Condition
Drug Resistant Epilepsy
Intervention / Treatment

-

Contacts and Locations

New York

Mount Sinai Hospital, New York, New York, United States, 10035

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Provision of signed and dated informed consent form
  • * Adults (18 years or older)
  • * Cognitively impaired adults are not excluded (i.e. will be included in the study)
  • * Established diagnosis of Drug Resistant Epilepsy (DRE) i.e. failed two or more appropriately chosen anti-seizure medications (ASMs)
  • * EEG consistent with focal or generalized epilepsy
  • * Patients must have \>4 focal aware, focal impaired aware, focal to bilateral tonic clonic or generalized tonic clonic seizures per month.
  • * Patients can be on \>/= 1 anti-seizure medication (ASM) at the time of enrollment on stable doses 12 weeks prior to initiation
  • * Patients on Epilepsy devices: Vagal nerve stimulator (VNS), Deep brain stimulator (DBS) or Responsive Nerve Stimulator (RNS) must have remained stable for at least 4 weeks before the screening visit. Adjustment of devices is not allowed during the study.
  • * Patients \<18 years of age
  • * Pregnant women
  • * Women that are breast feeding
  • * Patients who had \>21 days of seizure freedom in the last year.
  • * Patients with a history of status epilepticus within 3 months of screening
  • * Patients with a history of alcoholism of drug misuse within the last 2 years
  • * Unstable medical illness
  • * Serious or imminent suicidal or homicidal risk
  • * Patients with cardiovascular disease
  • * Patients with schizophrenia
  • * Patients with history of aneurysm or aortic dissection, arteriovenous malformation and intracerebral hemorrhage
  • * Patients that are immobile i.e. wheel chair bound, bed ridden individuals
  • * Patients on psychostimulants (amphetamines, methylphenidate etc.) and Monoamine oxidase inhibitors (selegiline, isocarboxazid, phenelzine etc.)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Madeline Fields,

Madeline Fields, MD, PRINCIPAL_INVESTIGATOR, Icahn School of Medicine

Lara Marcuse, MD, PRINCIPAL_INVESTIGATOR, Icahn School of Medicine

Study Record Dates

2024-12